JDRF and Eli Lilly to Fund Regenerative Medicine Research for Type 1 Diabetes
JDRF and Eli Lilly to Fund Regenerative Medicine Research for Type 1 Diabetes
Shares
JDRF and Eli Lilly signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate the insulin-producing cells destroyed by the disease. The goal of this research agreement is to understand how selected cells can be reprogrammed in order to convert them into insulin-producing cells in the body. This research is an example of regenerative medicine, a new frontier in science that replaces or regenerates new cells, tissues or organs, and while this particular research is early stage, it may lead to new approaches to treating type 1 diabetes.One research approach to finding novel treatments for type 1 diabetes may be to restore insulin production by regenerating insulin-producing cells within a person’s body. This involves triggering the body to grow its own new beta cells, either by growing existing ones – some are usually still active, even in people who have had diabetes for decades – or by creating new ones by reprogramming, which involves converting one type of cell in the body into a different type. If a therapeutic is developed that will allow for the regeneration of beta cells, it could potentially eliminate the need for insulin.
The JDRF-Lilly agreement will support a three-year, $1.4 million pre-clinical research effort to be led by Dr. Pedro Herrera of the University of Geneva. Previous research by Dr. Herrera showed that alpha cells in the pancreas can spontaneously, and without genetic manipulation, convert into beta cells. This suggests that alpha cell reprogramming could be a viable strategy for regenerating beta cells in people with type 1 diabetes.
JDRF and Michigan Medicine to Launch “Game-Changing”… Good news at the cutting edge of Type 1 diabetes research: Michigan Medicine and JDRF have jointly announced that they will establish a new Center of Excellence for advanced scientific…
Breakthrough Research on Encapsulation Device to… A device implanted into mice, coupled with a ground-breaking cell design, is a breakthrough toward a cure for Type 1 diabetes by allowing insulin-producing cells to function successfully in people…
JDRF Launches Northern California Center of… JDRF has announced the launch of the JDRF Northern California Center of Excellence, to accelerate high-impact research at Stanford University and the University of California, San Francisco, to develop cures for…
Chipping Away at Diabetes Research: An Interview… The 2019 recipient of the American Diabetes Association Kelly West Award for Outstanding Achievement in Epidemiology talks about the most pressing questions in the field of diabetes research, nutrition, and…
JDRF's Top 10 Diabetes Advances of 2019 JDRF is calling 2019, "a banner year for Type 1 diabetes breakthroughs." Check out their list below to find out their top ten diabetes advances of the year that make progress toward…